PCR

FIRST POLY BAGS IN US WITH 30% POST-RECYCLED CONTENT

Retrieved on: 
Friday, April 5, 2024
PCR, Certification, Government, EPR, ForeFront Records, Food packaging, ERP, Carbon, Marketing, Walmart, FDA, Gartner, Legislation

CHICAGO, April 5, 2024 /PRNewswire/ -- ForeFront Supply Chain Solutions is proud to supply the first polyethylene bag in the US with 30% post-consumer recycled content produced from FDA-compliant resins. This is the highest level of PCR available in flexible food packaging, which exceeds multiple new extended producer responsibility (EPR) and retailer regulations. ForeFront aims to support food manufacturers seeking compliance before packaging producer responsibility officially begins July 2025.

Key Points: 
  • ForeFront aims to support food manufacturers seeking compliance before packaging producer responsibility officially begins July 2025.
  • By 2025, Walmart will require 100% recyclable, reusable, or industrially compostable private brand packaging, including packaging with 20% post-consumer recycled content.
  • Brands that do not comply with post-recycled content packaging requirements risk heavy fines or having their products pulled from store shelves.
  • PCR content film can be combined with 10% post-industrial recycled or bio-based content.

QIAGEN introduces QIAstat-Dx Analyzer 2.0 with remote test results access, enhancing collaboration across healthcare system

Retrieved on: 
Monday, March 25, 2024
PCR, Comment, Patient, Software, Epidemiology, RAM, Senior, QIAGEN, QGEN, Medical device

The upgraded diagnostic system, powered by the new QIAstat-Dx Operational Module PRO with a 64‑bit processor and 4GB of RAM, introduces the Remote Results Application, still unique in the syndromic testing space.

Key Points: 
  • The upgraded diagnostic system, powered by the new QIAstat-Dx Operational Module PRO with a 64‑bit processor and 4GB of RAM, introduces the Remote Results Application, still unique in the syndromic testing space.
  • The new feature, accessible through the QIAsphere cloud and exclusively available with QIAstat‑Dx Analyzer 2.0, allows users to view, comment and confirm diagnostic test results directly from their desktop and mobile devices in any location, facilitating seamless collaboration across the healthcare system.
  • This enables greater flexibility and collaboration between central and regional labs, especially in decentralized testing, reducing diagnostic processing time and ensuring patients receive accurate results more quickly.
  • Alternatively, the QIAstat-Dx Analyzer 2.0 enables in-house visibility of test results over a shared network.

Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device

Retrieved on: 
Wednesday, March 20, 2024
MYGN, PCR, Arm, Genetic testing, Patent, Risk, Genetics, DNA, Snap, Myriad Genetics, Doctor of Philosophy, Medicine, Male, Pharmaceutical industry

11,932,907, titled Fetal Sex Determination Using Capillary Blood From Upper Arm, provides protection for Myriad’s SneakPeek Snap® products in the U.S through 2040.

Key Points: 
  • 11,932,907, titled Fetal Sex Determination Using Capillary Blood From Upper Arm, provides protection for Myriad’s SneakPeek Snap® products in the U.S through 2040.
  • Consumers place the Snap device on their arm, press the button, and the sample is collected in one to four minutes.
  • “We view this patent grant as recognition of our innovative approach to fetal sex testing using PCR-based techniques with any push-button blood collection device,” stated Dale Muzzey, PhD, Chief Scientific Officer at Myriad Genetics.
  • “This patent grant promotes SneakPeek Snap exclusivity in the US market through at least 2040 and provides an opportunity for licensing agreements with leading push-button blood collection device suppliers, positioning us as a strategic partner.”

Americhem has earned the EcoVadis Silver Medal for Sustainability

Retrieved on: 
Friday, April 5, 2024
Other Manufacturing, Environment, Textiles, Climate Change, Chemicals, Plastics, Manufacturing, Alternative Energy, Sustainability, Energy, Carbon, PCR, Solar energy, Cold, Biophysical environment, Silver, Human rights, PET, Guarantee of origin, LCA, Wind, Life-cycle assessment, Water, Safety, Sustainable procurement, Certification

Americhem, a globally recognized designer and manufacturer of custom color masterbatch, functional additives, engineered compounds, and performance technologies, has been awarded the Silver EcoVadis Medal.

Key Points: 
  • Americhem, a globally recognized designer and manufacturer of custom color masterbatch, functional additives, engineered compounds, and performance technologies, has been awarded the Silver EcoVadis Medal.
  • EcoVadis is a globally recognized assessment platform that rates businesses' sustainability in various categories.
  • View the full release here: https://www.businesswire.com/news/home/20240404483358/en/
    Americhem has earned the EcoVadis Silver Medal for Sustainability (Graphic: Business Wire)
    The EcoVadis rating also covers a broad range of non-financial management systems including Environmental, Labor and Human Rights, Ethics, and Sustainable Procurement impacts.
  • Americhem would like to thank EcoVadis for their commitment to ensuring that companies remain conscious in their efforts toward a more sustainable future.

Mission Bio Launches Sample Multiplexing for Tapestri to Unlock Critical Single-Cell Insights for Oncology and Genome Editing Markets

Retrieved on: 
Thursday, April 4, 2024
Health, Hospitals, Genetics, General Health, Clinical Trials, Pharmaceutical, Biotechnology, PCR, Mutation, B cell, DNA, BioLegend, Medicine, Cancer, Hospital, Drug development, Bone marrow, Mission, AOCS, Pathology, Vaccine

Mission Bio , a leader in single-cell multiomic solutions for precision medicine, today introduces sample multiplexing features for the company’s Tapestri Platform.

Key Points: 
  • Mission Bio , a leader in single-cell multiomic solutions for precision medicine, today introduces sample multiplexing features for the company’s Tapestri Platform.
  • Combining multiple samples into a single experiment will help lower this barrier to entry for academic researchers and de-risk the adoption for biopharma.
  • Sample multiplexing by genotyping, unique to Tapestri, uses the genetic information of the relevant variants obtained by bulk next-generation sequencing to distinguish samples.
  • Mission Bio’s multiplexing capabilities make single-cell technology more accessible to the biomedical community and has the potential to dramatically impact patient care in the future.”
    For more information about Tapestri, please visit www.missionbio.com .

Nucleix Demonstrates Potential of its PCR EpiCheck® Assay to Accurately Differentiate Between Small Cell Lung Cancer (SCLC) Subtypes

Retrieved on: 
Thursday, April 4, 2024
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Science, Oncology, Diagnosis, PCR, Plasma, Carcinoma, Cancer cell, Protocol, Biomarker, DNA, Classification, University, MD Anderson Cancer Center, DNA methylation, AACR, Liquid biopsy, SCLC, Medical imaging

Nucleix , a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced data from a pilot study demonstrating the potential of a simple PCR assay based on EpiCheck® technology to accurately differentiate between small cell lung cancer (SCLC) subtypes.

Key Points: 
  • Nucleix , a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced data from a pilot study demonstrating the potential of a simple PCR assay based on EpiCheck® technology to accurately differentiate between small cell lung cancer (SCLC) subtypes.
  • The Company is presenting the data in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, April 5-10.
  • The 13-marker PCR assay developed for this pilot study stemmed from data from a recent study published in Cancer Cell demonstrating the detection of SCLC using DNA methylation in plasma samples from heavy smokers, yielding a sensitivity of 94% and specificity of 95%.
  • In the data being presented at AACR, the 13-marker PCR assay correctly classified 97% of the SCLC tissue samples in a blinded cohort.

Oligonucleotides Global Markets Report 2024: Historical Market Revenue Data from 2020 to 2022, Estimates for 2023, and CAGR Projections through 2028 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 3, 2024
Biotechnology, General Health, Health, Genetics, Pharmaceutical, Diagnosis, Cytomegalovirus retinitis, PCR, Eurofins Scientific, Thermo Fisher Scientific, Disease, Oligonucleotide, CMV, ESG, Integration, Estimation, Research, RNA, DNA, Cancer, Competition, Infection, Agilent Technologies, Hepatitis, Spinal cord, In situ hybridization, Therapy, USD, FDA, Liver, Polymerase chain reaction, Fine chemical

The Global Oligonucleotides Market was valued at USD 7 Billion in 2023, and is expected to reach USD 11.7 Billion by 2028, rising at a CAGR of 11.00%.

Key Points: 
  • The Global Oligonucleotides Market was valued at USD 7 Billion in 2023, and is expected to reach USD 11.7 Billion by 2028, rising at a CAGR of 11.00%.
  • This report covers the worldwide market for oligonucleotide synthesis, which consists of four main product types: oligonucleotide drugs, synthesized oligos, equipment and reagents, and services.
  • Based on application, the market for oligonucleotide synthesis is divided into research diagnostics and therapeutics.
  • The report also covers approved drugs, the oligonucleotide synthesis process, innovative research, opportunities within the market and profiles of leading companies in the oligonucleotide synthesis industry.

DNA Methylation Detection Technology Market Research 2024 - Global Forecast to 2033 Featuring Prominent Players - Thermo Fisher Scientific, Illumina, QIAGEN, Zymo Research, and Agilent Technologies - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 2, 2024
Biotechnology, Genetics, Health, Diagnosis, PCR, Growth, Drug discovery, Thermo Fisher Scientific, Biomarker, Research, DNA, Competitive landscape, Real-time, Microarray, Cancer, Software, DNA methylation, Agilent Technologies, DSM-IV codes, QIAGEN, MSP, Prognosis, Marketing, Medicine, Fine chemical

The global DNA methylation detection technology market is projected to experience substantial growth over the forecast period 2023-2033.

Key Points: 
  • The global DNA methylation detection technology market is projected to experience substantial growth over the forecast period 2023-2033.
  • In the DNA methylation detection technology market, several key players dominate the landscape with their diverse range of products and solutions.
  • Thermo Fisher Scientific, Illumina, Inc. QIAGEN, Zymo Research Corporation, and Agilent Technologies, Inc. are among the prominent market players offering innovative tools and platforms for DNA methylation analysis.
  • The global DNA methylation detection technology market can be considered to be in the mature growth stage of its lifecycle.

Global and Regional MRD Testing Market Analysis Report 2024: Revolutionizing Cancer Patient Management, Rising Consumer Awareness Spurs Demand for MRD Testing - Forecast to 2033 - ResearchAndMarkets.com

Retrieved on: 
Monday, April 1, 2024
Surgery, Medical Devices, Hospitals, Genetics, Health Technology, Biotechnology, Radiology, Health, Oncology, Hospital, PCR, Flow cytometry, Chronic leukemia, Growth, Bone marrow, Incidence, Integration, Patient, NGS, IDT, Research, Health care, Multiple myeloma, Acquisition, Cancer, Medicare, Medicine, Karyotype, MRD, Haematopoietic system, Region, GRAIL, Throttle position sensor, Lymphoma, Polymerase chain reaction, Medical imaging

The "MRD Testing Market - Global and Regional Analysis: Focus on Technology, Target Detection, End User and Region Analysis - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "MRD Testing Market - Global and Regional Analysis: Focus on Technology, Target Detection, End User and Region Analysis - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.
  • The MRD testing market is driven by several factors, including the expansion in medicare coverage for MRD testing and the administration of solid tumor diagnosis.
  • In recent years, as consumer awareness has grown, there has been an increasing demand for MRD testing.
  • The global MRD testing market is a rapidly growing segment in the healthcare industry, driven by the increasing demand for accurate and sensitive methods to monitor and manage cancer patients.

Global Polymerase Chain Reaction (PCR) for qPCR, dPCR, Singleplex & Multiplex Markets, 2023-2024 and 2027: Disruption Looms, Syndromic Diagnostics Looks Unstoppable, The Instrumentation Curve - ResearchAndMarkets.com

Retrieved on: 
Friday, March 29, 2024
Science, Biotechnology, Research, Medical Supplies, General Health, Health, COVID-19, Medical Devices, Continue, PCR

6.21 Chelex-Based Protocol to Reduce Cost, Time for PCR Testing

Key Points: 

6.21 Chelex-Based Protocol to Reduce Cost, Time for PCR Testing
6.36 SARS- Testing Demand to Continue 'Through 2022, and Beyond'